Home › Upcoming votes › ResMed Inc.
Read the proxy statement on EDGARResMed Inc.: past votes
Ballot read from the proxy statement and checked. As listed in ResMed Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of Directors Director election |
Board | For | 11 nominees; support 90% to 99.8% |
| 2 | Ratification of Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm Auditor |
Board | For | — |
| 3 | Advisory Vote to Approve Named Executive Officer Compensation Say on pay |
Board | For | 90% support |
From ResMed Inc.’s Form 8-K, filed November 20, 2025, for the meeting held November 19, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Carol Burt | 90% | — |
| Elect Director: Jan De Witte | 99.2% | — |
| Elect Director: Christopher DelOrefice | 98% | — |
| Elect Director: Karen Drexler | 96% | — |
| Elect Director: Michael Farrell | 95% | — |
| Elect Director: Peter Farrell | 99% | — |
| Elect Director: Harjit Gill | 99.0% | — |
| Elect Director: John Hernandez | 99.2% | — |
| Elect Director: Nicole Mowad-Nassar | 99.8% | — |
| Elect Director: Desney Tan | 98% | — |
| Elect Director: Ronald Taylor | 94% | — |
| Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement ("s | 90% | — |
| Item of business 4: Approve the amendment and restatement of the ResMed Inc. 2009 Incentive Award Plan | 96% | — |
| Item of business 5: Approve the amendment and restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan | 99.7% | — |
The five managers that reported the most shares voted at ResMed Inc.’s November 19, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | Vanguard | First Sentier Investors (Australia) IM Ltd | Aware Super Pty Ltd as trustee of Aware Super | BlackRock | Fidelity |
|---|---|---|---|---|---|
| Elect Director: Carol Burt | For | — | — | For | For |
| Elect Director: Jan De Witte | For | — | — | For | For |
| Elect Director: Christopher DelOrefice | For | — | — | For | For |
| Elect Director: Karen Drexler | For | — | — | For | For |
| Elect Director: Michael Farrell | For | — | — | For | For |
| Elect Director: Peter Farrell | For | — | — | For | For |
| Elect Director: Harjit Gill | For | — | — | For | For |
| Elect Director: John Hernandez | For | — | — | For | For |
| Elect Director: Nicole Mowad-Nassar | For | — | — | For | For |
| Elect Director: Desney Tan | For | — | — | For | For |
| Elect Director: Ronald Taylor | For | — | — | For | For |
| Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our | For | For | For | For | For |
| Item of business 4: Approve the amendment and restatement of the ResMed Inc. 2009 Incentive Award Plan | For | — | — | For | For |
| Item of business 5: Approve the amendment and restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan | For | — | — | For | For |
| Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30 | For | — | — | For | For |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.